Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
Not yet recruiting
- Conditions
- Stem Cell Transplant Complications
- Interventions
- Other: CARPET prognostic model
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06022445
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Effect of Preoperative Oral Energy Drinks Compared to Warming Matress on Body Temperature During Combined Spinal-epidural Anesthesia for Elective Cesarean Delivery.
Not Applicable
Not yet recruiting
- Conditions
- Cesarean Section Complications
- Interventions
- Device: Warming matressOther: Oral energy drinks
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT06017076
Quality of Life Influencing Factors
Completed
- Conditions
- Paroxysmal Atrial Fibrillation
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT05974098
- Locations
- 🇨🇳
Shan Qu, Beijing, Beijing, China
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Phase 2
Not yet recruiting
- Conditions
- Non Squamous Non Small Cell Lung CancerEGFR Positive Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT05962021
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
Not Applicable
Recruiting
- Conditions
- Endometrial Neoplasm MalignantCarcinoma, EndometrioidEndometrial NeoplasmsEndometrial Neoplasm Malignant Stage IFertility Preservation
- Interventions
- Combination Product: Indication-extended Fertility-sparing Therapy
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT05945407
- Locations
- 🇨🇳
Peking University People's Hosoital, Beijing, Beijing, China
Soluble B7-H3 as a Biomarker for Osteosarcoma
Recruiting
- Conditions
- ProgressionBiomarkerOsteosarcomaSurveillance
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05942456
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
Phase 2
Recruiting
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT05932524
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD
Phase 3
Recruiting
- Conditions
- Acute Graft Versus Host Disease
- Interventions
- Drug: Corticosteroid
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 218
- Registration Number
- NCT05921305
- Locations
- 🇨🇳
Nanfang Hospital, Nanfang Medical University, Guangzhou, Guangdong, China
🇨🇳Peking University Institute of Hematology,, Beijing, Beijing, China
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Recruiting
- Conditions
- Hematologic MalignancyStem Cell Transplant Complications
- Interventions
- Combination Product: Beijing protocol
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05921318
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Ven+CAG
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05918198
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath